DEXCOM INC — Director's Dealing 2025

Mar 12, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2025-03-08

Reporting Person: Sylvain Jereme M (EVP, Chief Financal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-08	Common Stock	A	35906	—	Acquired	119684	Direct
2025-03-08	Common Stock	A	22798	—	Acquired	142482	Direct
2025-03-10	Common Stock	S	2670	$73.217	Disposed	139812	Direct
2025-03-10	Common Stock	S	3203	$74.0404	Disposed	136609	Direct
2025-03-10	Common Stock	S	1127	$74.7023	Disposed	135482	Direct

Footnotes

F1: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting from the date of grant as follows: 1/2 shall vest on March 8, 2026, 1/8 shall vest on May 22, 2026, 1/8 shall vest on August 22, 2026, 1/8 shall vest on November 8, 2026, and the remaining balance shall vest on March 8, 2027. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F3: This transaction was executed in multiple trades at prices ranging from $72.56 to $73.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F4: This transaction was executed in multiple trades at prices ranging from $73.56 to $74.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F5: This transaction was executed in multiple trades at prices ranging from $74.61 to $74.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F6: Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 252 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on February 28, 2025.